Dyadic International Inc (DYAI)

[dennisczy]

Thanks! I consulted a PhD in immunology to ask about the probability of success regarding glycoengineering of C1. he said that theoretically all possible with synthetic bio but not sure until proven.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070867/

he also pointed this out:
this is different from typical biopharma risk because there's no target risk or disease biology risk - they're trying to make existing famous antibodies. their timeline seems realistic ... haven't read enough about what's limiting tech but given time and partnership they're more likely to achieve goal

I consulted another anitbody engineer who is a PhD candidate in immunology (but notably he didn't look at the source material much) and he said that the 6 year time line is very optimistic.